286 related articles for article (PubMed ID: 34806469)
1. Clinical Outcome of Salvage Radiotherapy for Locoregional Clinical Recurrence After Radical Prostatectomy.
Lee SU; Cho KH; Kim JH; Kim YS; Nam TK; Kim JS; Cho J; Choi SH; Shim SJ; Kim JH; Chang AR
Technol Cancer Res Treat; 2021; 20():15330338211041212. PubMed ID: 34806469
[No Abstract] [Full Text] [Related]
2. Use of Concomitant Androgen Deprivation Therapy in Patients Treated with Early Salvage Radiotherapy for Biochemical Recurrence After Radical Prostatectomy: Long-term Results from a Large, Multi-institutional Series.
Gandaglia G; Fossati N; Karnes RJ; Boorjian SA; Colicchia M; Bossi A; Seisen T; Cozzarini C; Di Muzio N; Noris Chiorda B; Zaffuto E; Wiegel T; Shariat SF; Goldner G; Joniau S; Battaglia A; Haustermans K; De Meerleer G; Fonteyne V; Ost P; Van Poppel H; Montorsi F; Briganti A
Eur Urol; 2018 Apr; 73(4):512-518. PubMed ID: 29229176
[TBL] [Abstract][Full Text] [Related]
3. Comparison of hypofractionation and standard fractionation for post-prostatectomy salvage radiotherapy in patients with persistent PSA: single institution experience.
Murgic J; Jaksic B; Prpic M; Kust D; Bahl A; Budanec M; Prgomet Secan A; Franco P; Kruljac I; Spajic B; Babic N; Kruslin B; Zovak M; Zubizarreta E; Rosenblatt E; Fröbe A
Radiat Oncol; 2021 May; 16(1):88. PubMed ID: 33980277
[TBL] [Abstract][Full Text] [Related]
4. Natural history of 'second' biochemical failure after salvage radiation therapy for prostate cancer: a multi-institution study.
Tumati V; Jackson WC; Abugharib AE; Raj G; Roehrborn C; Lotan Y; Courtney K; Bagrodia A; Gahan JC; Zumsteg ZS; Folkert MR; Laine AM; Hannan R; Spratt DE; Desai NB
BJU Int; 2018 Mar; 121(3):365-372. PubMed ID: 28581200
[TBL] [Abstract][Full Text] [Related]
5. Use of androgen deprivation and salvage radiation therapy for patients with prostate cancer and biochemical recurrence after prostatectomy.
Ghadjar P; Aebersold DM; Albrecht C; Böhmer D; Flentje M; Ganswindt U; Höcht S; Hölscher T; Sedlmayer F; Wenz F; Zips D; Wiegel T;
Strahlenther Onkol; 2018 Jul; 194(7):619-626. PubMed ID: 29383406
[TBL] [Abstract][Full Text] [Related]
6. Long-term Outcome of Prostate Cancer Patients Who Exhibit Biochemical Failure Despite Salvage Radiation Therapy After Radical Prostatectomy.
Ying J; Wang CJ; Yan J; Liauw SL; Straka C; Pistenmaa D; Xie XJ; Lotan Y; Roehrborn C; Kim DN
Am J Clin Oncol; 2017 Dec; 40(6):612-620. PubMed ID: 26165416
[TBL] [Abstract][Full Text] [Related]
7. Macroscopic locoregional relapse from prostate cancer: which role for salvage radiotherapy?
Bruni A; Ingrosso G; Trippa F; Di Staso M; Lanfranchi B; Rubino L; Parente S; Frassinelli L; Maranzano E; Santoni R; Sighinolfi MC; Lohr F; Mazzeo E
Clin Transl Oncol; 2019 Nov; 21(11):1532-1537. PubMed ID: 30868389
[TBL] [Abstract][Full Text] [Related]
8. Outcomes of salvage radiotherapy for recurrent prostate cancer after radical prostatectomy.
Lee EK; Mui WH; Chan AW; Tung Y; Wong FC
Hong Kong Med J; 2018 Jun; 24(3):218-225. PubMed ID: 29807949
[TBL] [Abstract][Full Text] [Related]
9. Prostate-specific antigen after salvage radiotherapy for postprostatectomy biochemical recurrence predicts long-term outcome including overall survival.
Bartkowiak D; Thamm R; Bottke D; Siegmann A; Böhmer D; Budach V; Wiegel T
Acta Oncol; 2018 Mar; 57(3):362-367. PubMed ID: 28816074
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of PSMA ligand PET-based radiotherapy for recurrent prostate cancer after radical prostatectomy and salvage radiotherapy.
Oehus AK; Kroeze SGC; Schmidt-Hegemann NS; Vogel MME; Kirste S; Becker J; Burger IA; Derlin T; Bartenstein P; Eiber M; Mix M; la Fougère C; Belka C; Combs SE; Grosu AL; Müller AC; Guckenberger M; Christiansen H; Henkenberens C
BMC Cancer; 2020 Apr; 20(1):362. PubMed ID: 32349700
[TBL] [Abstract][Full Text] [Related]
11. Outcome after PSMA-PET/CT-based salvage radiotherapy for nodal recurrence after radical prostatectomy.
Rogowski P; Trapp C; von Bestenbostel R; Eze C; Ganswindt U; Li M; Unterrainer M; Zacherl MJ; Ilhan H; Beyer L; Kretschmer A; Bartenstein P; Stief C; Belka C; Schmidt-Hegemann NS
Eur J Nucl Med Mol Imaging; 2022 Mar; 49(4):1417-1428. PubMed ID: 34628521
[TBL] [Abstract][Full Text] [Related]
12. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
[TBL] [Abstract][Full Text] [Related]
13. Duration of Androgen Deprivation Therapy Influences Outcomes for Patients Receiving Radiation Therapy Following Radical Prostatectomy.
Jackson WC; Schipper MJ; Johnson SB; Foster C; Li D; Sandler HM; Palapattu GS; Hamstra DA; Feng FY
Eur Urol; 2016 Jan; 69(1):50-7. PubMed ID: 26004800
[TBL] [Abstract][Full Text] [Related]
14. The impact of salvage radiotherapy initiation at PSA ≤ 0.5 ng/ml on metastasis-free survival in patients with relapsed prostate cancer following prostatectomy.
Lee EE; Singh T; Hu C; Han M; Deville CJ; Halthore A; Greco S; Tran P; DeWeese T; Song DY
Prostate; 2023 Feb; 83(2):190-197. PubMed ID: 36316967
[TBL] [Abstract][Full Text] [Related]
15. Persistent Prostate-Specific Antigen After Radical Prostatectomy and Its Impact on Oncologic Outcomes.
Preisser F; Chun FKH; Pompe RS; Heinze A; Salomon G; Graefen M; Huland H; Tilki D
Eur Urol; 2019 Jul; 76(1):106-114. PubMed ID: 30772034
[TBL] [Abstract][Full Text] [Related]
16. Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial.
Carrie C; Hasbini A; de Laroche G; Richaud P; Guerif S; Latorzeff I; Supiot S; Bosset M; Lagrange JL; Beckendorf V; Lesaunier F; Dubray B; Wagner JP; N'Guyen TD; Suchaud JP; Créhange G; Barbier N; Habibian M; Ferlay C; Fourneret P; Ruffion A; Dussart S
Lancet Oncol; 2016 Jun; 17(6):747-756. PubMed ID: 27160475
[TBL] [Abstract][Full Text] [Related]
17. Long-term outcomes after high-dose postprostatectomy salvage radiation treatment.
Goenka A; Magsanoc JM; Pei X; Schechter M; Kollmeier M; Cox B; Scardino PT; Eastham JA; Zelefsky MJ
Int J Radiat Oncol Biol Phys; 2012 Sep; 84(1):112-8. PubMed ID: 22300563
[TBL] [Abstract][Full Text] [Related]
18. Combination of Androgen Deprivation Therapy and Salvage Radiotherapy versus Salvage Radiotherapy Alone for Recurrent Prostate Cancer after Radical Prostatectomy.
Yoo S; You D; Kim YS; Hong JH; Ahn H; Kim CS
Urol Int; 2017; 99(4):406-413. PubMed ID: 29020683
[TBL] [Abstract][Full Text] [Related]
19. Prognostic factors after salvage radiotherapy alone in patients with biochemical recurrence after radical prostatectomy.
Song W; Jeon HG; Sung HH; Jeong BC; Seo SI; Jeon SS; Choi HY; Lee HM
Int J Urol; 2016 Jan; 23(1):56-61. PubMed ID: 26502086
[TBL] [Abstract][Full Text] [Related]
20. Impact of Early Salvage Androgen Deprivation Therapy in Localized Prostate Cancer after Radical Prostatectomy: A Propensity Score Matched Analysis.
Park JW; Jang WS; Koh DH; Ham WS; Rha KH; Hong SJ; Choi YD
Yonsei Med J; 2018 Jul; 59(5):580-587. PubMed ID: 29869455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
